Home Logon FTA Investment Managers Blog Subscribe About Us Contact Us

Search by Ticker, Keyword or CUSIP       
 
 
First Trust Small Cap Growth AlphaDEX® Fund (FYC)
Investment Objective/Strategy - The First Trust Small Cap Growth AlphaDEX® Fund is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before the Fund's fees and expenses, of an equity index called the Nasdaq AlphaDEX® Small Cap Growth™ Index.
There can be no assurance that the Fund's investment objectives will be achieved.
Index Description According to the Index Provider
  • The Index is an "enhanced" index created and administered by Nasdaq, Inc. ("Nasdaq") which employs the AlphaDEX® stock selection methodology to select stocks from the Nasdaq US 700 Small Cap Growth™ Index that meet certain criteria.
  • Nasdaq constructs the Index by ranking the eligible stocks from the Nasdaq US 700 Small Cap Growth™ Index on growth factors including 3-, 6- and 12- month price appreciation, sales to price and one year sales growth, and separately on value factors including book value to price, cash flow to price and return on assets. All stocks are ranked on the sum of ranks for the growth factors and, separately, all stocks are ranked on the sum of ranks for the value factors. A stock must have data for all growth and/or value factors to receive a rank for that style.
  • Each stock receives either its growth or value score as its selection score based on its style designation as determined by Nasdaq. Only those stocks designated as growth stocks are eligible for the portfolio.
  • The top 262 stocks based on the selection score determined in the previous step comprise the "selected stocks". The selected stocks are divided into quintiles based on their rankings and the top ranked quintiles receive a higher weight within the index. The stocks are equally-weighted within each quintile.
  • The Index is reconstituted and rebalanced quarterly.
Fund Overview
TickerFYC
Fund TypeSmall Cap Growth
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon Corp
CUSIP33737M300
ISINUS33737M3007
Intraday NAVFYCIV
Fiscal Year-End07/31
ExchangeNasdaq
Inception4/19/2011
Inception Price$20.08
Inception NAV$20.08
Rebalance FrequencyQuarterly
Expense Ratio*0.70%
* As of 12/1/2023
Current Fund Data (as of 5/17/2024)
Closing NAV1$67.06
Closing Market Price2$67.09
Bid/Ask Midpoint$67.02
Bid/Ask Discount0.06%
30-Day Median Bid/Ask Spread30.16%
Total Net Assets$274,939,390
Outstanding Shares4,100,002
Daily Volume4,445
Average 30-Day Daily Volume12,245
Closing Market Price 52-Week High/Low$67.49 / $51.50
Closing NAV 52-Week High/Low$67.47 / $51.56
Number of Holdings (excluding cash)263
Top Holdings (as of 5/17/2024)*
Holding Percent
Oscar Health, Inc. (Class A) 0.96%
ImmunityBio, Inc. 0.90%
ADMA Biologics, Inc. 0.88%
PROCEPT BioRobotics Corporation 0.87%
IES Holdings, Inc. 0.83%
Zeta Global Holdings Corp. (Class A) 0.81%
Sweetgreen, Inc. (Class A) 0.80%
United States Lime & Minerals, Inc. 0.78%
Itron, Inc. 0.75%
RadNet, Inc. 0.75%

* Excluding cash.  Holdings are subject to change.

NAV History (Since Inception)
Past performance is not indicative of future results.
Distribution Information
Dividend per Share Amt (as of 5/19/2024)4$0.1555
30-Day SEC Yield (as of 4/30/2024)50.46%
12-Month Distribution Rate (as of 4/30/2024)60.48%
Index Yield (as of 4/30/2024)71.24%
Fund Characteristics (as of 4/30/2024)8
Maximum Market Cap.$6,521
Median Market Cap.$2,174
Minimum Market Cap.$123
Price/Book2.64
Price/Cash Flow11.09
Price/Sales1.71
Bid/Ask Premium/Discount (as of 5/17/2024)
  2023 Q1 2024 Q2 2024 Q3 2024
Days Traded at Premium 41 38 1 ---
Days Traded at Discount 209 23 34 ---
Top Sector Exposure (as of 5/17/2024)
Health Care 21.18%
Industrials 20.81%
Information Technology 14.77%
Financials 12.36%
Consumer Discretionary 11.22%
Real Estate 7.22%
Energy 5.37%
Communication Services 3.06%
Materials 2.98%
Consumer Staples 0.77%
Utilities 0.26%
Hypothetical Growth of $10,000 Since Inception (as of 5/16/2024) *